Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
61 results about "Esophageal reflux" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Medical Definition of Esophageal reflux. Esophageal reflux: A condition wherein stomach contents regurgitate or back up (reflux) into the esophagus (a long cylindrical tube that transports food from the mouth to the stomach). The food in the stomach is partially digested by stomach acid and enzymes.
Surgical instruments for treating gastro-esophageal reflux
InactiveUS6740082B2Augment objectInexpensive and disposableElectrotherapyEndoscopesSensor arrayFiber
Instruments for thermally-mediated treatment of a patient's lower esophageal sphincter (LES) to induce an injury healing response to thereby populate the extracellular compartment of walls of the LES with collagen matrices to altere the biomechanics of the LES to provide an increased intra-esophageal pressure for preventing acid reflux. A preferred embodiment is a bougie-type device for trans-esophageal introduction that carries conductive electrodes for delivering Rf energy to walls of the LES (i) to induce the injury healing response or (ii) to "model" collagenous tissues of the LES by shrinking collagen fibers therein. Typically, an Rf source is connected to at least one conductive electrode that may be operated in a mono-polar or bi-polar fashion. A sensor array of individual sensors is provided in the working end. A computer controller is provided, which together with feedback circuitry, is capable of full process monitoring and control of: (i) power delivery; (ii) parameters of a selected therapeutic cycle, (iii) mono-polar or bi-polar energy delivery, and (iv) multiplexing of current flow between various paired electrodes. The controller can determine when the treatment is completed based on time, temperature, tissue impedance or any combination thereof.
Owner:MEDERI RF LLC
Compositions for treatment of gastro-esophageal reflux disorders
The present invention provides compositions for treatment of gastro-esophageal reflux disorders. The compositions include at least two of the following: (i) one or more digestive enzymes; (ii) one or more probiotics; and (iii) stevia. Also provided are processes for preparing the compositions useful for treatment of gastro-esophageal reflux disorders, and methods of treating subjects against gastro-esophageal reflux disorders, which include administering to a subject a therapeutically effective amount of the compositions of the present invention.
Owner:EISENSTEIN JEREMY B
Oral-esophageal-gastric device to diagnose reflux and/or emesis
ActiveUS20110040211A1Simplify the viewing processMechanical/radiation/invasive therapiesElectromyographyMedicineCatheter
A system and method diagnoses esophageal reflux in a patient. A catheter includes a first pressure sensor configured to measure intra-abdominal pressure when the catheter is inserted into the stomach of a patient. A second pressure sensor is located proximal to the distal tip and configured to measure intra-thoracic pressure. A pH indicator is carried by the catheter body and configured to indicate that reflux has occurred in response to an involuntary reflex cough test. A processing device is configured to receive data regarding the first and second pressure sensors and regarding the pH indicator and process that data and assess if reflux is present during the involuntary epoch.
Owner:PNEUMOFLEX SYST
Gastro-esophageal reflux control system and pump
ActiveUS7967780B2Without causing deleterious effects on the esophageal structuresReduce contentSurgeryDilatorsOesophageal tubeLiquid medium
An enteral feeding unit that reduces the occurrence of gastro-esophogeal-pharynegal reflux during feeding includes an automatable feeding pump with a feedback sensor for sensing a relative pressure in a patient's stomach and esophagus, and a regulator system for controlling and monitoring feeding rate to the patient as a function of the relative gastro-esophageal pressure. The system includes a stomach probe that provides a fluid-tight closure of the esophagus. The stomach probe includes a tampon-bladder for watertight closure of the esophagus, in which the tampon-bladder is formed of flexible and / or elastic material. At least an inner cavity of the bladder is provided for the reception of a fluid medium. A prescribed pressure for the medium in the tampon-bladder (53) is maintained by an inner lumen forming the stomach probe, from which an outer hose-like lumen (62) extending to the tampon-bladder (53) is so arranged that between the outer lumen (62) and the inner lumen (61) a channel is formed connected to the inner cavity of the tampon-bladder (53) arranged on the outer lumen (62) by a number of openings (57). The inner cavity (58) of the tampon-bladder (53) is connected via a canal formed between the inner and outer lumina (62) with a suitably graded reservoir or equalizing vessel for the liquid medium situated above the tampon-bladder and outside the patient.
Owner:AVENT INC
Esomeprazole magnesium sustained-release dropping pill and preparation method thereof
InactiveCN101269037ASubstance content changeSuitable for useOrganic active ingredientsDigestive systemDiseaseReflux esophagitis
The invention discloses a pharmaceutical preparation used for treating erosive reflux oesophagitis, a gastroesophageal reflux disease, maintaining a long-term therapy to prevent the recurrence of oesophagitis for a cured patient, controlling the symptoms of gastroesophageal reflux diseases, eradicating helicobacter pylori jointly medicated with an appropriate antimicrobial therapy, healing duodenal ulcer related to helicobacter pylori infections and preventing the recurrence of peptic ulcer related to helicobacter pylori, and particularly relates to a prepared sustained-release oral formulation adopting esomeprazole magnesium as the ingredient. The pharmaceutical preparation aims to supplement the deficiency of the prior art and provide a sustained-release esomeprazole magnesium dropping pill. The sustained-release esomeprazole magnesium dropping pill overcomes the defects in the prior art effectively, guarantees no occurrence of an obvious quality change for the drug during the effective storage period and has the advantages of controllable release time, full release and high bioavailability simultaneously.
Owner:北京博智绿洲医药科技有限公司
Materials and methods for the treatment of gastroesophageal reflux disease
InactiveUS20030216387A1Safe and effective treatmentReduce adverse effectsBiocideNervous disorderDiseaseSide effect
The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.
Owner:ARYX THERAPEUTICS
Gel type enteral nutrient
ActiveUS20100040739A1Simple structureLittle changeOrganic active ingredientsHydrolysed protein ingredientsSolid matterPhysical property
A gel type enteral nutrient, which is excellent in the form-maintaining capability of solid matter (gel) in the stomach, is not easily disintegrated or dissolved even depending upon a pH change, shows little change in the physical properties such as water liberation, or the like even during long-term stage, can be thermally sterilized and has a preferable property passing through a feeding tube, can be prepared by blending agar and alginic acid and / or its salt, and further soybean protein as a nitrogen source. It is expected to exert effects that neither gastro-esophageal reflux nor leakage of the nutrient occur when intaking the gel type enteral nutrient of the present invention.
Owner:EN OTSUKA PHARM CO LTD
Medicine for treating gastroesophageal reflux disease and functional dyspepsia
InactiveCN101143143AImprove toleranceHigh synergistic effectDigestive systemSolution deliveryLansoprazoleRabeprazole
A combination preparation for remedying the gastroesophageal reflux disease (GERD) and the functional dyspepsia is characterized in that the prescription of the combination preparation consists of a proton pump depressor and a gastrointestinal power drug of itopride; the proton pump depressor is selected from one of a Pantoprazole, a Omeprazole, a Esomeprazole, a Lansoprazole, a Rabeprazole, a Tenatoprazole and a Leminorazole, wherein the Pantoprazole is preferential, and at the same time the neutral form of the basic salt of the proton pump depressor is also included, such as Naplus, Mg2plus, Ca2plus, Kplus or Li plus salt and a pure optical stereoisomer of the proton pump depressor or an active metabolite of the proton pump depressor; the gastrointestinal power drug is the itopride and a ramification of the itopride or one of the medicinal salts of the itopride; in the combination preparation, the weight ratio of the Pantoprazole and the itopride is 2 to 5 to 2 to 7. The invention has important affect for remedying the gastroesophageal reflux disease and the functional dyspepsia, and the preparation method of the invention is simple and convenient; the cost is low; the invention is fit for being orally taken by the patient; the invention has good conformance performance, high curative effect, low recrudescence rate and little adverse reaction.
Owner:沈阳东宇药业有限公司
Combined drug of pantoprazole and domperidone
InactiveCN101961334AHas an acid-suppressing effectInhibition of secretionPowder deliveryOrganic active ingredientsTreatment effectDuodenal ulcer
The invention provides a combined drug of pantoprazole and domperidone and in particular provides application of pantoprazole and domperidone to preparing combined injections for treating gastric ulcer, duodenal ulcer, gastro-esophageal reflux diseases or functional dyspepsia. The invention also provides the combined injections for treating gastric ulcer, duodenal ulcer, gastro-esophageal reflux diseases or functional dyspepsia, including different specifications of unit preparations, pantoprazole and domperidone for simultaneous, respective or successive administration and preparations prepared by pharmaceutically acceptable vectors. The weight ratio of pantoprazole and domperidone is 1:1-5:1, and the pantoprazole and domperidone contain excipients, stabilizing agents, etc. Through combined injection administration, the invention improves the bioavailability of pantoprazole and domperidone and ensures the treatment effects to be obviously better.
Owner:CHENGDU ZIHAO PHARMA
Anti-reflux infant nutrition
ActiveUS20120213858A1Thickened in stomachReduce the amount requiredMilk preparationDispersion deliveryWhey proteinInfant nutrition
An infant formula for preventing gastro-esophageal reflux is disclosed comprising whey protein and / or casein, a galactomannan thickener, and a fermented milk-derived product.
Owner:NUTRICIA
Special medical food thickening component for inhibiting esophageal regurgitation and preparation method thereof
ActiveCN110353271AThickening achievedAchieve viscosity increaseFood ingredient as thickening agentInorganic compound food ingredientsCarrageenanAdditive ingredient
The invention discloses a special medical food thickening component for inhibiting esophageal regurgitation. The special medical food thickening component for inhibiting esophageal regurgitation is composed of the following ingredients (by mass): 2-6% of guar gum, 2-5% of locust bean gum, 2-6% of xanthan gum, 1-2% of carrageenan, 15-20% of gelatin, 8-12% of Arabic gum, 0.5-1% of polydextrose, 1-2%of sodium bicarbonate or potassium bicarbonate and 47-68% of glycerin. The invention also discloses a preparation method of the above special medical food thickening component. The special medical food thickening component for inhibiting esophageal regurgitation can form a cortex-wrapped gel-layer structure to facilitate swallowing; bicarbonate and gastric juice cause a swelling effect to accelerate cortex dissolution for pore-forming; rapid swelling helps thickening; and a gelatin-Arabic gum and guar gum-xanthan gum high-viscosity compound interspersed structure helps thickening efficiently.
Owner:SHAANXI UNIV OF SCI & TECH
Materials and methods for the treatment of gastroesophageal reflux disease
The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.
Owner:ARYX THERAPEUTICS
Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders
ActiveUS20130040987A1Reduce adverse effectsIncrease pressureBiocideOrganic chemistryRefluxGastroparesis
The subject invention provides stereoisomeric compounds of formula (X):wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.
Owner:RENEXXION LLC
Oral-esophageal-gastric device to diagnose reflux and/or emesis
A system and method diagnoses esophageal reflux in a patient. A catheter includes a first pressure sensor configured to measure intra-abdominal pressure when the catheter is inserted into the stomach of a patient. A second pressure sensor is located proximal to the distal tip and configured to measure intra-thoracic pressure. A pH indicator is carried by the catheter body and configured to indicate that reflux has occurred in response to an involuntary reflex cough test. A processing device is configured to receive data regarding the first and second pressure sensors and regarding the pH indicator and process that data and assess if reflux is present during the involuntary epoch.
Owner:PNEUMOFLEX SYST
Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders
ActiveUS20070078265A1Stable storageSafe metabolismOrganic chemistryDigestive systemNervous systemCentral nervous system
The subject invention provides methods and / or processes for making stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.
Owner:RENEXXION LLC
Stereoisomeric Compounds And Methods For The Treatment Of Gastrointestinal And Central Nervous System Disorders
ActiveUS20080085921A1Reduce adverse effectsIncrease pressureBiocideOrganic chemistryRefluxGastroparesis
The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.
Owner:RENEXXION LLC
Infusion bag with rabeprazole sodium injection and infusion liquor in isolated two chambers and preparation method thereof
InactiveCN1827106AGood effectClinical useOrganic active ingredientsPowder deliveryVeinReflux esophagitis
This invention is a solid-liquid double chambers transfusion of injection bemegridethiazole, and it contains a bigger chamber and a smaller one. The smaller chamber is used to fill injection bemegridethiazole, while the bigger one is used to fill transfusion liquid. In the smaller chamber, each application unit contains 5mg-800mg sterile bemegridethiazole; In the bigger chamber, each application unit contains 100mg-50000mg isotonic conditioning agent, 0mg-4000mg sodium sulfite and 50mL-1000mL water for injection. The solid-liquid double chamber transfusion of injection bemegridethiazole is mainly used to short-term treat duodenum ulcer, gastric ulcer, pathological hyper stomach-acid secretion and reflux esophagitis. Closely before using this product, press the bigger chamber with hand and the two chambers will be dredged, rock back and forth to mix the medicine liquid even and intravenous drip. This production brings convenience to rescue personnel in clinical usage.
Owner:肖广常 +1
Stomach tube with core temperature detecting and esophageal reflux preventing actions
PendingCN112546403ARealize blockingDoes not affect normal inflowBalloon catheterDiagnostic recording/measuringDiseaseLiquid diet
Owner:SHANDONG UNIV QILU HOSPITAL
Six-in-one anti-reversion particles and preparation method thereof
InactiveCN111840457AIt has the effect of promoting qi and relieving painAntiemeticDigestive systemGranular deliveryEsophagitisLindera aggregata
The invention provides six-in-one anti-reversion particles and a preparation method thereof. The six-in-one anti-reversion particles are prepared from the following components in parts by weight: 600gof lily, 200 g of lindera aggregata, 200g of radix aucklandiae, 300g of vinegar-processed rhizoma corydalis, 300g of rhizoma cyperi, 180g of coptis chinensis, 60g of fructus evodiae and 240g of fructus aurantii. The invention also provides the preparation of the six-in-one anti-reversion particles. The preparation method comprises the following steps: S1) adding 5 times of water into the radix linderae, the radix aucklandiae, the rhizoma cyperi and the fructus aurantii, distilling for 3 hours, receiving distillate, standing, taking out a volatile oil layer for later use, and filtering a distilled water solution to obtain filtrate and medicine residues; S2) mixing the decoction dregs, lily, vinegar processed corydalis tuber, coptis chinensis and fructus evodiae, adding 8 times of water, decocting for three times, then filtering, combining filtrates, and standing overnight; and S3) taking out the supernatant of the combined filtrate. The six-in-one anti-reversion particles have a remarkable clinical effect on liver-stomach stagnated heat type esophagitis, have no recurrence and no side effect after drug withdrawal, and are convenient to popularize and use.
Owner:贵州中医药大学第一附属医院
Oral compositions for the treatment of gastroesophageal reflux
ActiveUS20190314402A1Relief to oesophagitisGreat tasteOrganic active ingredientsDispersion deliveryGlycerolMucoadhesion
The present invention describes a mucoadhesive composition comprising chondroitin sulfate, xyloglucan and glycerol for use in the treatment and prevention of gastroesophageal reflux. It is also described a process for preparing such composition, a dosage form for its administration and a kit comprising the same.
Owner:ALFASIGMA SPA
Methods and devices for endosonography-guided fundoplexy
ActiveUS8784437B2Reduce gastroesophageal refluxEasily drawnSuture equipmentsSurgical needlesEsophageal wallGuided intervention
The present invention relates to a tissue securement system, device and method for endoscopy or endosonography-guided transluminal interventions whereby a ligation or anchor is placed and secured into soft tissue. An objective of this invention is to provide a method to reduce gastroesophageal reflux by endosonography-guided intervention. Specifically, endosonography is used to insert a ligation element through the esophageal wall, through the diaphragmatic crus and into the fundus of the stomach. This ligation element placed from the esophagus and around the Angle of His to create a barrier to gastroesophageal reflux.
Owner:ADVENT MEDICAL
Traditional Chinese medicine composition for treating acid reflux
InactiveCN109550032APlay a synergistic roleFree from careDigestive systemPlant ingredientsEsophagitisLicorice roots
The invention provides a traditional Chinese medicine composition for treating acid reflux, which comprises the following raw materials in parts by weight: 2-15g of radix curcumae, 2-10g of cape jasmine, 2-15g of bamboo shavings, 2-10g of pseudo-ginseng, 3-12g of ginger, 10-30g of pearl shell, 3-12g of light fermented soya bean, 5-20g of cuttlebone, 3-12g of honey-fried licorice root, 5-25g of loquat leaf, 3-15g of dried tangerine peel, 5-25g of dandelion, and 5-25g of jujube. The preparation method comprises the following steps: taking the raw material medicines for cleaning and removing impurities, adding water to decoct the materials and merging filtrates, concentrating and cooling the materials, adding ethanol to make an alcohol content of 20 to 80%, recovering the ethanol, and concentrating a supernatant into a thick paste for standby; and drying the thick paste to prepare a corresponding dosage form, wherein the dosage form includes a pill, a lozenge, pulvis, a powder, a particulate agent or a decoction bag. The traditional Chinese medicine composition can cure the acid reflux, treat the esophagitis, esophageal reflux and pharyngitis caused by the acid reflux, and can restorethe elasticity of the sphincter, simultaneously purify the stomach, and regulate and consolidate the gastric mucosa.
Owner:李谚明
Pharmaceutical composition for treating gastroesophageal reflux
InactiveCN106620084AControl refluxClearance functionDigestive systemPlant ingredientsDuodenogastric RefluxPeristalsis
The invention relates to a traditional Chinese medicinal composition for treating gastroesophageal reflux. The traditional Chinese medicinal composition is characterized by being prepared from the following medicines in parts by weight: 6-9 parts of an extract of root of three-nerved spicebush, 6-9 parts of a radix astragali extract, 1.5-3 parts of resina liquidambaris, 6-9 parts of perilla stem, 3-6 parts of rhizoma typhonii, 6-9 parts of radix paeoniae alba, 1.5-3 parts of a glycyrrhiza liquid extract and 100ml of sesame oil. The pharmaceutical composition provided by the invention has the beneficial effects that the pharmaceutical composition can control reflux, promote peristalsis and expurgation functions and can control duodenogastric reflux. The traditional Chinese medicine (the pharmaceutical composition), which can promote qi circulation and remove stasis, promote spasmolysis, tonify spleen, relieve restlessness and promote emptying, can achieve an effect of relieving pain.
Owner:宋丽静
Compositions for the symptomatic relief of stomach pain or gastrooesophageal reflux
InactiveUS20140037730A1Reduce impactSubject to a greater chemical and enzymatic aggressionBiocideDigestive systemStomach PainFatty acid
Owner:GAGO DE SANTOS ANGEL MANUEL
Integrated premature infant body position auxiliary instrument
PendingCN111449879APrevent apneaReduce intracranial hemorrhageBaby-incubatorsLight therapyPatient roomCare personnel
The invention relates to the technical field of medical auxiliary instruments, and particularly discloses an integrated premature infant body position auxiliary instrument. The integrated premature infant body position auxiliary instrument can be used for premature infants in neonatal wards or neonatal care rooms during hospitalization, and is a suitable tool provided for body position intervention of clinical nursing personnel; and the scope of developmental care of the premature infants is expanded. The integrated premature infant body position auxiliary instrument is particularly suitable for the premature infants during hospitalization, and the integrated component structure is beneficial for the premature infants to maintain flexion similar to intrauterine physiological flexion and support movement; apnea caused by bad body positions is avoided, and the risks of intracranial hemorrhage, gastroesophageal reflux and the like are reduced; and therefore, self-coordination and nerve development after birth are promoted.
Owner:SHANGHAI CHILDRENS MEDICAL CENT AFFILIATED TO SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Chymosin for the prevention and treatment of gastrointestinal disorders
InactiveUS20080131487A1Easy to processSimple to useMilk preparationDispersion deliveryDiseaseZymogen
The present invention is directed to medical or dietary treatments comprising administration of a zymogen such as chymosin or other rennins. Embodiments of the invention are directed to treating infant colic, heartburn, gastro-esophageal reflux (GER), gastro-esophageal reflux disease (GERD), irritable bowel syndrome, and recurrent abdominal pain. The invention is also directed to improving absorption of calcium from milk for osteoporosis patients. Further the present invention may have a very positive effect on life quality for groups with different chronic digestion problems such as ulcerous colitis, multiple sclerosis, migraines, weight disorders and diabetes. Infants may be given several drops of a composition containing chymosin prior to every feeding, regardless of whether they are bottle or breast-fed. The composition containing chymosin can also be incorporated into a food product such as drinking milk or baby formula. The rennin helps infants break down milk proteins so that the milk can be transformed into cheese pulp in the stomach, mimicking the process occurring in the stomachs of normal infants.
Owner:NUTRICHYM
Esophagus and stomach asymmetric anastomat with anti-reflux effect
PendingCN114601519AInhibit refluxHas anti-reflux effectSuture equipmentsSurgical staplesFood bolusEsophageal peristalsis
The esophagus and stomach asymmetric anastomat is characterized in that the end face of a nail bin is formed by connecting and closing two arc-shaped plates bent in the same direction end to end to form an arc-shaped cavity, nail outlet holes in the arc-shaped plates are formed around the arc-shaped cavity, and a cutter is consistent with the arc-shaped cavity in shape and is attached to the edge of the inner side wall of the arc-shaped cavity; a nail cutting board on the bottom face of the nail abutting base is formed by digging a cutting groove consistent with the arc-shaped cavity in the end face of the nail bin in shape in a circular board, and nail abutting grooves matched with the nail outlet holes in position and shape are formed in the circular board around the cutting groove. After anastomosis, redundant esophageal and gastric tissues on the anterior wall deform into the stomach to form a tongue piece, and the tongue piece is matched with manual folding and suturing of the posterior wall in the gastral cavity to form a valvular tongue piece closing, so that a valvular structure is formed together. The anastomotic stoma channel is in a valvular closed state when no food is eaten, and the anastomotic stoma is opened due to the peristalsis pressure of the esophagus and the expansion effect of a food mass during eating, so that the effect of preventing stomach-esophageal reflux in a cardia shape is achieved.
Owner:HUAIAN JINOU MEDICAL BIOTECHNOLOGY CO LTD
Traditional Chinese medicine compound composition for treating refractory gastroesophageal reflux
ActiveCN112717045AHas anti-inflammatory propertiesIncrease gastric emptying rateDigestive systemPlant ingredientsInflammatory factorsWolfiporia extensa
The invention discloses a traditional Chinese medicine compound composition for treating refractory gastroesophageal reflux. The traditional Chinese medicine compound composition is prepared from the following components in parts by weight: 10-20 parts of inula flower, 10-20 parts of processed rhizoma pinelliae, 10-20 parts of processed rhizoma cyperi, 4-14 parts of caulis perllae, 10-20 parts of raw folium eriobotryae, 10-20 parts of pericarpium citri reticulatae, 10-20 parts of poria cocos, 20-40 parts of cuttlebone and 20-40 parts of fried semen raphani. The traditional Chinese medicine compound composition for treating refractory gastroesophageal reflux provided by the invention has an anti-inflammatory effect, can improve the gastric emptying rate of rabbits, improve the small intestine peristalsis of the rabbits and improve the small intestine propulsion rate, can reduce the expression of inflammatory factors in gastric tissues, has no adverse reaction and no obvious toxic or side effect, and is safe and effective.
Owner:SHANGHAI CHANGZHENG HOSPITAL
Semi-solidified nutritional agent for solving problem of enteral nutrition intolerance and preparation method of semi-solidified nutritional agent
PendingCN112890179AAvoid high viscosity and difficult swallowing problemsImprove liquidityFood ingredient as thickening agentVitamin food ingredientsNutritionWarm water
The invention discloses a semi-solidified nutritional agent for solving the problem of enteral nutrition intolerance and a preparation method of the semi-solidified nutritional agent. The semi-solidified nutritional agent is prepared from the following components: 500-750 parts of carbohydrate, 135-200 parts of protein, 85-100 parts of fat, 10-50 parts of low-methoxy pectin, 0.1-2 parts of a vitamin compound and 5-80 parts of a mineral compound, wherein the mineral compound contains calcium hydrogen phosphate. After being brewed with warm water, the prepared semi-solidified nutritional agent is similar to a flowing liquid of a common beverage in an environment with a pH value of 7+ / -0.2, so that a patient (such as a dysphagia patient with weakened tracheal closure muscle group control force) can take the nutritional agent orally conveniently, and the problem that a semi-solidified nutritional agent in the prior art is too high in viscosity and difficult to swallow is avoided; and after the liquid is drunk, calcium in calcium hydrogen phosphate is promoted to be separated out into calcium ions under the action of gastric acid, the calcium ions and free methoxyl groups in low-methoxyl pectin are subjected to bridging reaction, and an eggshell-shaped relatively stable ion binding type semi-solidified gel structure is formed, so that intestinal nutrition intolerance reactions such as gastroesophageal reflux, diarrhea and the like are inhibited.
Owner:CHENGDU SHANGYI INFORMATION TECH CO LTD
Cough prescription
ActiveCN106620440AReduce adverse reactionsGood cough suppressantAnthropod material medical ingredientsRespiratory disorderSide effectAcute bronchitis
The invention relates to a traditional Chinese medicine composition for treating cough, made from 3-15 parts of mulberry silkworm, 3-15 parts of cicada slough, 5-15 parts of roasted herb of Chinese ephedra, 5-15 parts of apricot seed, 5-15 parts of roasted loquat leaf, 5-15 parts of roasted root of sessile stemona, and the like. The traditional Chinese medicine composition can effectively treat cough due to various causes, has light side effects, and can effectively treat, particularly, cough variant asthma, acute bronchitis, and gastro-esophageal reflux induced cough.
Owner:杨道文
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com